70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.
Robbert C A M Gielen, Coralie Poncet, Laura J van 't Veer et al.
✦ AI-curated · Sources linked
In 30 seconds
The MINDACT trial explored the role of the 70-gene signature (MammaPrint) in patients over 50 with early-stage HR-positive, HER2-negative breast cancer. This randomized controlled trial found that in clinical high/genomic low-risk patients, the 8-year distant metastasis-free survival (DMFS) was 87.9% for tumors >2 cm, 91.3% for grade 3 tumors, and 89.6% for those with nodal involvement, indicating limited benefit from adjuvant chemotherapy.
Key findings
- 8-year DMFS was 87.9% for tumors larger than 2 cm in the no ACT group.
- 8-year DMFS was 91.3% for patients with grade 3 tumors without ACT.
- 8-year DMFS was 89.6% for patients with 1-3 involved lymph nodes not receiving ACT.
- Absolute 8-year DMFS benefit for ACT versus no ACT was 1.2%, -2.2%, and 0.7% for the respective groups.
Why it matters
Understanding the prognostic value of the 70-gene signature in high-risk subgroups can aid clinicians in making informed decisions about the necessity of adjuvant chemotherapy, potentially reducing overtreatment in certain patients.